Mural Oncology plc
$2.64
(as of Apr 24, 4:00 PM EST)
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
Ticker Information for Mural Oncology plc
Stock Price
$2.64
Ticker Symbol
MURA
Exchange
NASDAQ
Industry Information for Mural Oncology plc
Sector
Healthcare
Industry
Biotechnology
Company Description for Mural Oncology plc
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.
Fundamentals for Mural Oncology plc
Market Capitalization
$47,722,392
EBITDA
$-134,750,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-7.58
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
17,228,300
Percent Owned by Insiders
5.60%
Percent Owned by Institutions
62.36%
52-Week High
52-Week Low
Technical Indicators for Mural Oncology plc
Analyst Ratings for Mural Oncology plc
Strong Buy
0
Buy
2
Hold
2
Sell
0
Strong Sell
0
News About Mural Oncology plc
Mar 25, 2025, 6:30 AM EST
Based on overall survival data observed in interim analysis in platinum-resistant ovarian cancer, Mural will not progress trial to final analysis
See more.
Mar 11, 2025, 4:01 PM EST
Interim analysis of overall survival in potentially registrational phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer expected in late Q1/early Q2 2025
See more.
Feb 2, 2024, 2:15 AM EST
The quest for prime biotech stocks for gains will always be relevant. See more.
Jan 15, 2024, 4:51 PM EST
Companies within the biotechnology industry are very interesting to investors because they see wild swings in share price following positive or negative news, particularly in the case of small biotech companies. See more.